###### Article summary

Article focus
=============

-   Recent evidence suggests that vitamin D~3~ has potent extraskeletal effects, such as suppression of inflammation and strengthening of mucosal immunity by induction of antimicrobial peptides.

-   Data from observational studies suggest that low levels of 25-hydroxyvitamin D~3~ are associated with an increased risk of respiratory tract infections.

-   Results from a limited number of randomised controlled trials on the protective role of vitamin D~3~ against respiratory tract infections are inconclusive and thus additional studies are warranted.

Key messages
============

-   Therefore we designed and carried out a randomised controlled trial where a large dose (4000 IU) of vitamin D~3~ was given to patients with an increased susceptibility to infections for 1 year.

-   The main conclusion is that vitamin D~3~ supplementation reduces symptoms and antibiotic consumption among patients with an increased frequency of respiratory tract infections. Thus, vitamin D~3~ supplementation may be an alternative strategy to reduce antibiotic use among patients with recurrent respiratory tract infections.

Strengths and limitations of this study
=======================================

-   A high daily dose of vitamin D~3~ was used, the study time was a full year covering all seasons and patients with an increased frequency of respiratory tract infections were studied.

-   A single study centre, small sample size (n=140) and a selected group of patients.

Introduction {#s1}
============

Vitamin D was discovered when it was noted that rachitic children were improved by exposure to sunlight.[@R1] It was later shown by Holick *et al*[@R2] that vitamin D~3~ is synthesised in the skin under the influence of ultraviolet light. Vitamin D~3~ is further hydroxylated in the liver to 25-hydroxyvitamin D~3~, which is considered to reflect the vitamin D status of an individual patient.[@R3] The final activation to the active form 1,25-dihydroxyvitamin D~3~ (1,25(OH)D~3~) requires 1-α-hydroxylase activity. This enzyme (also designated CYP27B1) is expressed in the kidney but also in many other cell-types, including epithelial and immune cells.[@R4] The active vitamin D~3~ (1,25(OH)D~3~) binds to the vitamin D receptor (VDR), which belongs to the nuclear receptor family. Active vitamin D~3~ is only present in minute amounts in the circulation and local activation in target cells is crucial for vitamin D-mediated effects on the immune system.[@R5]

Low levels of 25-hydroxyvitamin D~3~ are associated with an increased risk of tuberculosis[@R6; @R7; @R8] and respiratory tract infections.[@R9] The mechanism is not fully elucidated but vitamin D~3~ has been shown to induce antimicrobial peptides in immune cells.[@R10] In addition, active vitamin D~3~ (1,25(OH)D~3~) has broad anti-inflammatory effects on the adaptive immune system by shifting the T helper cell pool from a Th1/Th17-response to a Th2/Treg-dominated response.[@R11] [@R12] Vitamin D~3~ has also been shown to suppress the Th2-response in allergic bronchopulmonary aspergillosis.[@R13] Thus, vitamin D~3~ modulates both the adaptive and innate immune system.[@R14] The bulk of data on vitamin D~3~ and infections stems from in vitro experiments and retrospective observational studies. Results from randomised controlled trials (RCTs) where the effects of vitamin D~3~ on infections have been investigated (reviewed by Yamshchikov *et al*[@R15]) are not conclusive and larger clinical trials are therefore warranted.

We designed a study to test the hypothesis that 4000 IU of vitamin D~3~ given daily to patients with antibody deficiency and frequent respiratory tract infections for 1 year could prevent or ameliorate infections. In addition, we investigated whether genetic polymorphisms in genes involved in the effect and/or metabolism of vitamin D~3~ have an influence on the outcome of vitamin D~3~ supplementation.

Methods {#s2}
=======

Study design {#s2a}
------------

A prospective, randomised, double-blind placebo-controlled study of vitamin D~3~ supplementation in patients with an increased susceptibility to respiratory tract infections. The study was approved by the local Ethical Committee and the Swedish Medical Product Agency and was performed in accordance with the declaration of Helsinki. Written informed consent was obtained from all study participants. The study was registered at [www.clinicaltrials.gov](www.clinicaltrials.gov) prior to inclusion of the first patient (NCT01131858). The EudraCT number is 2009-011758-16. The full protocol is available from the corresponding author upon request.

Sample size calculation {#s2b}
-----------------------

The sample size was based on the assumption that the intervention would reduce the number of days with symptoms from 42 (210 points) to 28 days (140 points), that is, a reduction of the infectious burden by 30%. Given this assumption, a sample size of 60 patients per study group was predicted to provide the study 90% power at a significance level of p=0.02 (Student\'s t test). To compensate for predicted exclusion of participants, the groups were increased to include 70 patients per treatment arm. Importantly, the significance level of p=0.02 was chosen in the power calculation to ensure that a sufficient number of patients were recruited in order to avoid a type II error in the primary analysis. However, the conventional and widely accepted significance level of p=0.05 was used for statistical analyses of the primary and secondary endpoints.

Participants {#s2c}
------------

Patients at the Immunodeficiency Unit, Karolinska University Hospital, Huddinge, Sweden, were included between March and June 2010 by the study nurses (SH, ML and KJ). Inclusion criteria were age 18--75 years and an increased susceptibility to respiratory tract infections; that is, \>42 days with symptoms from the respiratory tract during a 12-month period prior to study inclusion. Patients registered at the Immunodeficiency Unit are closely followed up with a diary of symptoms and antibiotic consumption. Thus, the patients are trained and used to apply such an instrument to assess their infectious status. Data from patients' standard diary were used as an instrument in order to assess patients for eligibility, both via telephone and by the responsible physician (PB and ACN) prior to inclusion. Patients with selective IgA-deficiency (*D80.2*), IgG-subclass deficiency (*D80.3*) and common variable immune disorder (CVID, *D83.0*) as well as patients without a defined immunological diagnosis (*D89.9*) were included. Exclusion criteria were prophylactic treatment with antibiotics, history of hypercalcaemia or stones in the urinary tract, sarcoidosis, ongoing supplementation with vitamin D~3~ exceeding 400 IU/day, HIV-infection and pregnancy.

Interventions {#s2d}
-------------

Patients were randomised to 12 months' treatment with vitamin D~3~ (Vigantol, 4000 IU/day, Merck GmbH, Darmstadt, Germany) or placebo oil. One drop contained 500 IU vitamin D~3~ or placebo oil (Miglyol oil, Merck GmbH, Darmstadt, Germany) and the participants were asked to take eight drops daily. The participants had to mark their daily symptoms of infection in a diary, which was sent via regular mail to the study site every month. The following data were recorded: symptoms from the respiratory tract, ears and sinuses, treatment with antibiotics, numbers of bacterial cultures, times and reasons of visits to hospitals, frequency of travelling abroad and adherence to study drug.

Outcomes {#s2e}
--------

The primary outcome was a composite infectious score, based on a daily patient-reported questionnaire and included five parameters: symptoms from the respiratory tract, ears and sinuses, malaise and use of antibiotics (see online supplementary figure S1), each parameter gave 1 point/day. The occurrence of x-ray verified pneumonia gave three additional points per day for a period of 7 days. Thus, a pneumonia resulted in 3×7 points=21 extra points. Patients were specifically instructed to record only symptoms related to ongoing respiratory tract infections. Symptoms related to infections at other sites (urinary tract, wounds, etc) as well as non-infectious symptoms were reported as adverse events. Secondary outcomes were serum levels of 25-hydroxyvitamin D~3~ (at baseline and after 3, 6, 9 and 12 months), numbers of bacterial cultures, microbiological findings and levels of antimicrobial peptides (LL-37 and HNP1-3) in nasal fluid (at baseline and after 6 and 12 months). In addition, six post hoc genotype analyses were performed in all participants. Analyses of single nucleotide polymorphisms (SNPs) were carried out for VDR (Taq1 and Foq1), CYP27B1, CYP24A1, CYP2R1 and vitamin D binding protein (GC). Safety tests included plasma levels of creatine, calcium, phosphate and albumin, measured at baseline and after 3, 6, 9 and 12 months. At inclusion, urine-HCG (human chorionic gonadotropin) in women was measured and p-parathyroid hormone was measured in both genders. The results of the safety tests were reviewed by an independent and unblinded consultant physician. Two blinded physicians (PB and ACN) were responsible for inclusion and all medical visits to the study site (Immunodeficiency Unit, Karolinska University Hospital, Huddinge, Sweden).

Randomisation and statistical analysis {#s2f}
--------------------------------------

Participants were randomised to 12 months' treatment with vitamin D~3~ (Vigantol, 4000 IU/day) or placebo oil. Block randomisation with a block size of ten was used to ascertain equal group sizes. Staff at Karolinska Trial Alliance was responsible for randomisation procedures. In the statistical analysis, continuous variables were compared using Mann-Whitney U test or linear regression and dichotomous variables by Fisher\'s exact test or logistic regression. Regressions of log-transformed infectious scores were performed both unadjusted (simple regression) and with adjustment for potential confounders (multiple regression).

Statistical methods: primary analysis {#s2g}
-------------------------------------

The distribution of the infectious score was found to be skewed, thereby violating the normal assumption of the prespecified t test analysis. Hence, scores were log-transformed prior to analysis. Further, the randomisation had resulted in age distributions that were not entirely balanced between the two groups. Since there might be concerns that such imbalance could influence the results of the study, the original analysis plan was extended with a multivariable analysis adjusting for potential confounders. In this linear regression model based on log-transformed values of the primary outcome (the total infectious score) and its individual components, adjustment was made for age, gender, smoking, type of immune deficiency and significant comorbidities (respiratory or non-respiratory). Because of the transformation procedure, the adjusted effect of vitamin D~3~ is expressed as a ratio between the score in the vitamin D~3~ and the placebo group. In this multiplicative model, an effect size of 1 indicates identical outcome in the two study groups and statistically non-significant results are recognised by CIs encompassing the value 1.

To explore potential divergent effects on different organ systems, both adjusted and unadjusted analyses were repeated separately for each individual item of the infectious score. In addition, the temporal aspects of the vitamin D~3~ effect were investigated by dividing the study period into four 90-day periods (starting on the first day of treatment) and repeating the analyses separately for each time period. 'Ear' and 'sinus' symptoms as well as 'antibiotic use' occurred at low frequencies and for these entities normal distributions could not be achieved despite data transformation. Thus, the adjusted analyses of these individual items were based on multivariable logistic regression, after coding the symptom (or antibiotic therapy) as present or absent during the course of the study. However, this only applies to analysis of the individual items, and not to the primary analysis of the total infectious score, where all item scores were added as originally described.

Most postrandomisation exclusions were due to patients failing to fill out the symptoms diary. Hence, no intention-to-treat (ITT) analysis based on actual outcome data could be performed. However, the potential impact of dropouts was addressed in an ITT analysis based on multiple imputation of missing outcome data. In the imputation process, pooled estimates were derived from 100 datasets created by means of multivariate imputation by chained equations and predictive mean matching for the same covariates as in the adjusted per-protocol analysis.

Detailed descriptions of randomisation and blinding, sampling of nasal fluid, measurement of antimicrobial peptides, measurement of 25-hydroxyvitamin D~3~, genotyping and statistical analyses of secondary outcomes are presented in the supplementary methods section.

Results {#s3}
=======

Baseline data {#s3a}
-------------

A total of 286 patients were first assessed for eligibility but 144 were not included because they did not fulfil all inclusion criteria; \<42 days with infection/year (n=35), lacked other inclusion criteria (n=42), or declined to participate (n=67). The remaining 142 patients were further screened and 140 patients were included in the study. Of these, 70 were randomised to vitamin D~3~ supplementation and 70 to placebo ([figure 1](#BMJOPEN2012001663F1){ref-type="fig"}). The groups did not differ with regard to gender, IgG replacement therapy, smoking, baseline 25-hydroxyvitamin D~3~ levels, type of immune defect or comorbidities ([table 1](#BMJOPEN2012001663TB1){ref-type="table"}). Patients with subclass deficiency, selective IgA deficiency (sIgAD), CVID and patients without a defined immunological diagnosis (ND) but with \>4 bacterial respiratory tract infections/year were included. IgG replacement therapy was most common in the CVID group (100%) and in the subclass deficiency group (63%), and also frequent in the other groups (ND, 54% and sIgAD, 38%, see online supplementary table S1). Patients allocated to the placebo group were slightly younger than patients in the treatment group (p=0.025, data not shown). During the course of the study, 16 patients left the study prematurely (8 patients from each study group) and consequently 124 patients were included in the main per-protocol analysis. Reasons for dropout included elevated parathyroid hormone (n=2), withdrawn consent (n=5), adverse events (n=1), prescription of vitamin D outside the study (n=1), failure to complete diary (n=4) or non-compliance to study medication (n=3; [figure 1](#BMJOPEN2012001663F1){ref-type="fig"}).

![Study outline.](bmjopen2012001663f01){#BMJOPEN2012001663F1}

Primary endpoint: infectious score {#s3b}
----------------------------------

One year of vitamin D~3~ treatment was associated with a significantly reduced total infectious score both in the unadjusted (n=124, p=0.024; [table 2](#BMJOPEN2012001663TB2){ref-type="table"}) and in the adjusted analyses (n=124, p=0.040; [table 2](#BMJOPEN2012001663TB2){ref-type="table"}; [figure 2](#BMJOPEN2012001663F2){ref-type="fig"}A,B and see online supplementary table S2). The unadjusted relative score in the intervention group was 0.754 (95% CI 0.591 to 0.963, p=0.024, n=124) corresponding to a 25% reduction and after adjustment for potential confounders, the relative score was 0.771 (95% CI 0.604 to 0.985, p=0.04), corresponding to a 23% reduction ([table 2](#BMJOPEN2012001663TB2){ref-type="table"}). According to the temporal analysis, the effect of vitamin D~3~ supplementation tended to improve with time ([figure 2](#BMJOPEN2012001663F2){ref-type="fig"}A). The absolute unadjusted score per patient was 202 points for the vitamin D group and 249 points for the placebo group, a significant reduction of 47 points per patient (p=0.023, Mann-Whitney U test, see online supplementary table S3).

###### 

Primary endpoint

  Endpoint        Univariable regression model (unadjusted values)   Multiple regression model (adjusted values)                                    
  --------------- -------------------------------------------------- --------------------------------------------- ------- ------- ---------------- -------
  Total score     0.754                                              0.591 to 0.963                                0.024   0.771   0.604 to 0.985   0.040
  Airway          0.857                                              0.697 to 1.053                                0.141   0.871   0.706 to 1.074   0.200
  Ear\*           0.721                                              0.352 to 1.465                                0.367   0.695   0.320 to 1.501   0.357
  Sinus\*         0.583                                              0.280 to 1.198                                0.144   0.594   0.265 to 1.328   0.204
  Malaise         0.845                                              0.692 to 1.032                                0.098   0.845   0.689 to 1.036   0.108
  Antibiotics\*   0.355                                              0.154 to 0.784                                0.012   0.365   0.153 to 0.872   0.023

Treatment effect calculated as the ratio between infectious scores in the vitamin D~3~ and the placebo groups. Due to low frequencies, endpoints marked with asterisks (\*) were coded as binary outcomes (ie, present or absent in each patient) and compared by means of logistic regression. In these cases, the effect refers to OR of experiencing the outcome at least once during the course of the study (The data are based on n=124 patients).

![Primary endpoint. The adjusted total relative infectious score (A) is expressed 'per quarter' (3-month periods). The adjusted 1-year scores (total score, airway, malaise, ear, sinus and antibiotics) are depicted in a Forest-plot (B) together with 95% CI. Effects are presented as relative scores (total score, airway and malaise) or OR (ear, sinus, antibiotics and indicated with asterisks).](bmjopen2012001663f02){#BMJOPEN2012001663F2}

When the individual items of the infectious score were analysed separately, all point estimates indicated a reduction in the treatment group ([table 2](#BMJOPEN2012001663TB2){ref-type="table"}, see online supplementary figure S2), although only antibiotic consumption reached statistical significance ([figure 2](#BMJOPEN2012001663F2){ref-type="fig"}B and see online supplementary figure S2, panel E). The adjusted OR for antibiotic use was 0.365 (95% CI 0.153 to 0.872, p=0.023, n=124), that is, a 63.5% reduction of the odds of antibiotic use in the intervention group ([table 2](#BMJOPEN2012001663TB2){ref-type="table"}). The absolute values were 33 days on antibiotics for the placebo group and 16 days for the vitamin D~3~ group, that is, a reduction of 17 days in the vitamin D~3~ group (see online supplementary table S3). The temporal trends for specific symptoms and antibiotic consumption were similar to the total score and reached statistical significance for 'ear'-symptoms (n=124, p=0.041) and for 'malaise' (n=124, p=0.053) in the final quarter of the study (see online supplementary figure S2, panels B and C).

Analysing the primary outcome according to ITT (n=140) produced results virtually identical to those of the per-protocol analysis. In the unadjusted ITT analysis, vitamin D~3~ reduced the total infectious score by 25% (relative score 0.752, 95% CI 0.588 to 0.962, p=0.024) and after adjustment for potential confounders the reduction was 23% (relative score 0.767, 95% CI 0.599 to 0.982, p=0.036).

Serum levels of 25-hydroxyvitamin D~3~ {#s3c}
--------------------------------------

Serum 25-hydroxyvitamin D~3~ levels did not differ between the groups at baseline ([table 1](#BMJOPEN2012001663TB1){ref-type="table"}) but already after 3 months the intervention group had a significantly higher level of 25-hydroxyvitamin D~3~ (133.4 vs 66.6 nmol/l, p\<0.001; [figure 3](#BMJOPEN2012001663F3){ref-type="fig"}). This increase remained throughout the study ([figure 3](#BMJOPEN2012001663F3){ref-type="fig"}).

###### 

Baseline data

                                 Vitamin D~3~   Placebo
  ------------------------------ -------------- ---------
  Number                         70             70
  Age (mean)                     55.4           50.8
  Female                         52/70          50/70
  Male                           18/70          20/70
  IgG-replacement                39/70          42/70
  Smoking                        4/70           6/70
  25-OH levels (mean) (nmol/l)   51.5           46.9
  Immunological diagnosis                       
   sIgA-deficiency               9/70           9/70
   IgG subclass                  27/70          30/70
   CVID                          6/70           4/70
   ND                            28/70          27/70
  Concomitant disease                           
   No other disease              16/70          18/70
   Lung: Asthma                  27/70          25/70
   Lung: BE                      5/70           7/70
   Lung: COPD                    5/70           4/70
   Other disease\*               17/70          16/70

Mann-Whitney U test was used for comparisons of age and 25-OH vitamin D~3~. Fisher\'s exact test was used for all other comparisons.

\*'other disease' includes hypertension, body pain, hypothyroidism and gastritis as most common diagnoses.

BE, bronchiectasis; COPD, chronic obstructive pulmonary disease; CVID, common variable immuno deficiency; ND, increased susceptibility to infections without a defined immunological disorder.

![Secondary endpoint. Vitamin D levels. Serum was collected at days 0, 3, 6, 9 and 12 months and levels of 25-hydroxyvitamin D~3~ were measured. Values are expressed as mean±95% CI.](bmjopen2012001663f03){#BMJOPEN2012001663F3}

Bacterial cultures and microbiology {#s3d}
-----------------------------------

During the course of the study, 173 microbiological samples were obtained in the vitamin D~3~ group (n=62, 2.79/patient) and 301 in the placebo group (n=62, 4.85/patient; p=0.010; [table 3](#BMJOPEN2012001663TB3){ref-type="table"}). The number of samples with at least one positive finding was higher in the placebo group, with close to statistical significance (p=0.052), while the fraction of positive samples was similar for both groups ([table 3](#BMJOPEN2012001663TB3){ref-type="table"}). Significantly more patients had a microbiological sample taken from the respiratory tract (≥1 sample) during the study period in the placebo group; OR 2.63 (95% CI 1.17 to 5.92; [table 3](#BMJOPEN2012001663TB3){ref-type="table"}).

###### 

Bacterial cultures

                                                           Vitamin D~3~   Placebo         Significance
  -------------------------------------------------------- -------------- --------------- --------------
  Number of samples per patient (mean, n=62/62)            2.79           4.85            p=0.010\*
  Number of positive samples per patient (mean, n=62/62)   1.01           2.02            p=0.052\*
  Fraction positive cultures (%)                           63/173 (36%)   125/301 (41%)   p=0.28\*\*
  Patients with ≥1 sample taken                            38/62 (61%)    50/62 (81%)     p=0.029\*\*

\*Mann-Whitney U test.

\*\*Fisher\'s exact test.

In total, the vitamin D~3~ group generated 76 positive microbiological findings (bacteria or fungi), compared with 159 in the placebo group (p=0.023). There was no difference between the groups for the traditional respiratory pathogens (*Haemophilus influenza*, *Moraxella catharralis* and *Streptococcus pneumonia*), but there were significantly fewer findings of *Streptococcus aureus* (p=0.019) and fungi (p=0.028, *Candida* spp. and *Aspergillus* spp.) in the treatment group ([table 4](#BMJOPEN2012001663TB4){ref-type="table"}). Likewise, significantly fewer vitamin D~3~-treated patients had a bacterial culture positive for *S aureus* (p=0.019) or fungal species (p=0.058), although the latter difference did not reach statistical significance ([table 4](#BMJOPEN2012001663TB4){ref-type="table"}).

###### 

Microbiological findings

  Microorganism                Number of findings (total)   Number of patients                             
  ---------------------------- ---------------------------- -------------------- --------- ------- ------- ---------
  *Haemophilus influenzae*     28                           27                   p=0.46    10/62   13/62   p=0.64
  *Moraxella catharralis*      8                            17                   p=0.39    7/62    10/62   p=0.60
  *Streptococcus pneumoniae*   7                            6                    p=0.74    4/62    5/62    p=1.00
  *Staphylococcus aureus*      6                            33                   p=0.010   4/62    14/62   p=0.019
  *Enterobacteriacae*          8                            8                    p=0.39    4/62    7/62    p=0.53
  *Pseudomonas aeruginosa*     8                            15                   p=0.68    3/62    4/62    p=1.00
  *Fungal infection*           11                           53                   p=0.028   4/62    12/62   p=0.058
  Total                        76                           159                  p=0.023                   

Mann-Whitney U test was used to analyse the total number of findings, whereas Fisher\'s exact test was used for analysis of the number of patients (fraction) with a specific finding.

Vitamin D treated patients with subclass deficiency left significantly fewer bacterial or fungal cultures than placebo-treated patients with this diagnosis; seven cultures in the vitamin D group (n=22) versus 47 cultures in the placebo group (n=24) (see online supplementary table S4). Also the number of patients that had ≥1 bacterial culture taken was significantly fewer in the placebo group (12/22 vs 22/24, p=0.0065, see online supplementary table S4). There was no significant effect of other immunological diagnoses on bacterial cultures or microbiology (see online supplementary table S4).

Since concomitant lung disease may be an important factor for vitamin D mediated effects on respiratory immunity, we performed a detailed analysis of bacterial cultures and microbiology of patients with asthma, bronchiectasis (BE) and chronic obstructive pulmonary disease (COPD). The numbers of patients with these diagnoses were quite small, which preclude any firm conclusions regarding any effect. However, there was a trend---however not significant---that vitamin D-treated patients with asthma produced fewer bacterial cultures (average 2.9 cultures/patient vs 7.0 cultures/patients, p=0.080, see online supplementary figure S3) and fewer positive cultures than placebo-treated asthmatics (average 0.6 positive cultures/patients vs 2.7/patient in the placebo group, p=0.052, see online supplementary figure S3). In addition, vitamin D-treated asthma patients showed significantly fewer cultures positive for fungi (*Candida* and *Aspergillus*) compared with placebo-treated asthmatics (p=0.0476, see online supplementary table S5). For BE or COPD patients there was no clear trend or significant effect in bacterial cultures or microbiology.

Levels of antimicrobial peptides in nasal fluid {#s3e}
-----------------------------------------------

There was no statistically significant difference between the vitamin D~3~ or placebo groups when nasal fluids were analysed for the presence of antimicrobial peptides (AMPs). Initially, the levels of both LL-37 and HNP1-3 tended to be higher in the placebo group (see online supplementary figure S3, panels A and B). However, after 12 months the microbiological pattern was reversed and no primary pathogens could be detected in nasal swabs from vitamin D~3~-treated patients (n=25, p=0.039; see online supplementary figure S4, panel C). The placebo-treated patients exhibited the same mix between normal flora and primary pathogens at all three sampling points (0, 6 and 12 months; see online supplementary figure S4, panel C).

SNP variants and treatment effect {#s3f}
---------------------------------

Most genetic variants did not affect the primary endpoint. However, patients carrying the 'AA' genotype in the CYP2R1-gene, encoding the 25-hydroxylase enzyme, had a larger benefit of vitamin D~3~-supplementation (--55%) compared to AG or GG carriers (--6%) (n=124, p=0.046 for interaction, see online supplementary table S6).

Adverse events {#s3g}
--------------

In total, the vitamin D~3~ group reported 38 adverse events (AEs) versus 56 AEs in the placebo group. The most common symptoms in the treatment group were headache (n=5) and lumbago (n=5), whereas placebo-treated patients reported paresthesias (n=8), diverticulitis (n=4) and urinary tract infection (n=4) as most frequent AEs ([table 5](#BMJOPEN2012001663TB5){ref-type="table"}, see online supplementary table S7). There was a general trend towards the number of adverse events being higher in the placebo group. Significantly more patients in the placebo group reported cardiovascular problems, such as heart failure, hypertonia and thrombosis (p=0.028). For gastrointestinal and other (non-respiratory) infections there was also a trend favouring the vitamin D~3~ group (p=0.058 and 0.09, respectively). No clinically relevant changes in serum levels of calcium, phosphate, creatine or albumin could be observed (see online supplementary figure S5). There was one severe adverse event in each group (rabdomyosarcoma in the vitamin D~3~ group and lung bleeding in the placebo group), both judged as being unrelated to the study drug.

###### 

Adverse events

  Organ                          Vitamin D~3~ n (%)   Placebo n (%)   p Value
  ------------------------------ -------------------- --------------- ---------
  CNS                            11 (29)              10 (18)         1.00
  Gastrointestinal               4 (11)               12 (21)         0.058
  Cardiovascular                 0 (0)                6 (11)          0.028
  Infections (other than RTI)    2 (5)                8 (14)          0.09
  Musculoskeletal                10 (26)              10 (18)         1.00
  Respiratory (non-infectious)   2 (5)                4 (7)           0.68
  Skin                           5 (13)               2 (4)           0.44
  Other                          4 (10)               4 (7)           1.00
  Total                          38                   56              

Number of reports. Fisher\'s exact test was used for between group comparison (the data are based on AE-reports from n=62 patients/arm).

CNS, central nervous system, RTI, respiratory tract infection.

Discussion {#s4}
==========

The main conclusion from this long-term RCT is that vitamin D~3~ supplementation reduces the total burden of respiratory tract infections. The primary endpoint was composed of five different parameters that patients recorded daily throughout the study year. All point estimates favoured the vitamin D~3~ group and a statistically significant effect was seen on both the total score and on the probability of receiving antibiotics (p\<0.05). The effect on the infectious score was evident both in analysis per-protocol and according to ITT, and withstood adjustment for potential confounders. In addition, the number of bacterial cultures and microbiological findings was significantly reduced in the intervention group. These findings are potentially important and support that Vitamin D~3~ supplementation may prevent respiratory tract infections and reduce antibiotic consumption, particularly in patients with hypogammaglobulinaemia or with an increased frequency of respiratory tract infections.

However, our study has several limitations: First, the choice of primary endpoint may be questioned since it relies solely on patient-reported information. To compensate for inherent problems with patient-reported data, the evaluation instrument was designed to cover many aspects of an infectious episode, including various symptoms as well as antibiotic consumption. Together the reported data formed an 'infectious score', which constituted the primary endpoint of the study. Similar composite scores have successfully been applied to different diseases, such as tuberculosis (TB-score[@R16]), pneumonia (CURB-65[@R17]) and bacterial meningitis (BMS-score[@R18]). Notably, vitamin D supplementation had a major effect on the odds of taking antibiotics during the study period (a reduction by 63.5%). In addition, the absolute number of days on antibiotics was reduced by 50% (from 33 days in the placebo group to 16 days in the intervention group), which was statistically significant both in the adjusted and unadjusted analyses ([table 1](#BMJOPEN2012001663TB1){ref-type="table"}). However, despite the relatively modest reduction for the other components of the primary endpoint the overall infectious score was significantly reduced---mainly as a result of the large effect on the antibiotic parameter---both in the unadjusted and in the adjusted analyses ([table 1](#BMJOPEN2012001663TB1){ref-type="table"} and [figure 2](#BMJOPEN2012001663F2){ref-type="fig"}). It is important to interpret the statistical significance in light of our power calculation, which was based on a significance level of p=0.02. In the power calculation, the significance level was reduced from 0.05 to 0.02 in order to increase the statistical power at the p=0.05 level. This approach was incorrect, and the targeted power (at the p=0.05 level) should instead have been increased without altering the p-value threshold. However, we have used the widely accepted significance level p=0.05 in the statistical analyses for both the primary and secondary endpoints, respectively. Another potential problem was that the patient population was very heterogeneous with regard to immune deficiency and concomitant diseases. We adjusted for these factors in the multivariable analyses of the primary endpoint, but the sample sizes in each subgroup were too small to draw any conclusions of effects in specific disease groups. However, a detailed post hoc analysis of the relation between immunological diagnosis, concomitant lung disease and the secondary endpoints 'taken bacterial cultures', 'positive bacterial' cultures and 'microbiological findings' was performed. There was a clear trend that vitamin D-treated patients with subclass deficiency and/or asthma produced fewer bacterial cultures, fewer positive cultures and fewer fungal cultures (see online supplementary tables S4 and S5 and figure S3). Although this analysis may lack precision by the small number of patients included, it could have clinical implications regarding target groups for vitamin D~3~ supplementation.

Nevertheless, our double-blind RCT has several strengths. For example, we chose a high daily dose of vitamin D~3~ based on published calculations on metabolism and effects on immunity.[@R14] [@R19] Other RCTs using lower doses of vitamin D~3~, 400--2000 IU/day, have mainly been negative with regard to the prevention of infections.[@R20] [@R21] However, one study using 1200 IU/day showed a significant reduction of influenza among school children in Japan.[@R22] Notably, also studies using higher doses of vitamin D~3~ have been negative. Martineau *et al* used 400 000 IU vitamin D~3~ during 42 days (9523 IU/day) with the aim of shortening time to sputum conversion in tuberculosis. No significant effect on the primary endpoint could be observed in that study, except in a subgroup with the *tt* genotype in the VDR gene.[@R23] A recent study investigated whether 100 000 IU vitamin D~3~/month (3333 IU/day) could reduce the incidence of COPD exacerbations. There was no significant effect on the primary endpoint, although a post hoc analysis revealed that patients with a low vitamin D~3~ level at baseline had a significant effect of vitamin D~3~ supplementation.[@R24]

Importantly, our study is the first to utilise high daily doses for an extended period of one full year. Thus, we covered all four seasons, which was important in Sweden with a known seasonal variation in 25-hydroxyvitamin D~3~ levels.[@R25] Two previous RCTs were performed during the winter season---when vitamin D levels are low---but only during 4[@R22] and 6 months,[@R20] respectively. Previous RCTs have been conducted during shorter periods; 42 days,[@R23] 6 weeks[@R26] and 12 weeks,[@R21] respectively. Interestingly, we observed a clear time-dependent effect suggesting that a long-term supplementation approach (\>6 months) may be necessary to affect immunity. To expand on the results of a previous study in healthy individuals where no difference between the intervention and placebo groups was observed,[@R21] we chose a study population with frequent RTIs and at least 42 days with infection during the year prior to inclusion. Notably, patients in the study represent a selected group of individuals with frequent RTI, although the immune disorders that they represent (sIgAD, IgG-subclass deficiency and patients with no defined immune disorder) are generally mild in character and dominated by mucosal RTIs. We also included a small number of CVID-patients, which can be considered to be a more severe immune disorder, but all these patients are treated with IgG replacement therapy and thus well controlled. Hence, the results from this study cannot directly be applied to the general healthy population. Nevertheless, the results provide solid support for additional interventional studies of vitamin D~3~, especially in groups consuming large amounts of antibiotics.

The mechanism of the observed effects remains largely unknown. Vitamin D~3~ modulates the immune response at many levels, such as induction of AMPs, skewing of T-cells from Th1/Th17 to Tregs as well as general anti-inflammatory effects.[@R14] Here, we investigated the role of AMPs in nasal fluid. However, we could not detect any significant changes of LL-37 or HNP1-3 during the study period, but noted that placebo-treated patients tended to have higher levels of AMPs after 1 year of treatment. This was paralleled by a shift of the microflora in the nasal compartment that could explain the unexpected finding of higher AMP-levels in the placebo group. Recently, it was shown that 1,25 (OH)~2~-vitamin D~3~ induces both HNP1-3 and LL-37 in nasal fluid of healthy volunteers,[@R27] supporting that LL-37 may indeed be induced in vivo. However, our study design did not allow such conclusions but rather support that vitamin D~3~ affect mucosal immunity, leading to a shift of the microflora. Recently, we showed that the bacterial composition in nasal swabs is an important determinant of AMP-levels in nasal fluid.[@R28]

Given that vitamin D~3~ induces LL-37 in epithelial cells and that LL-37 kills bacteria in vitro, we expected a reduction of the classical bacterial pathogens *H influenza*, *M catharralis* and *S pneumonia* in the intervention group. However, the frequency of these bacteria was not reduced but a reduction of *S aureus* and fungal species that often colonise the airways was observed. This could be explained by specific effects by vitamin D~3~ on immunity against *S aureus*. In fact, vitamin D~3~ induces human β-defensin-2 (HBD-2) with bactericidal activity against *S aureus*.[@R29] A recent study showed that low vitamin D~3~ levels were associated with an increased risk of being colonised by this bacterium.[@R30] Further, vitamin D~3~ affects immunity against *C albicans*, which indicates direct effects of vitamin D~3~ on human immunity.[@R31] Alternatively, it is possible that vitamin D~3~ may have prevented symptomatic viral infections, which prompted patients to leave a bacterial sample from the airways. Interestingly, there is both mechanistic and clinical evidence that vitamin D~3~ can prevent viral infections,[@R32; @R33; @R34] although we did not address this in the current study.

Notably, we observed a prominent increase in the serum concentration of 25-hydroxyvitamin D~3~, which indicated good compliance and tolerability of the study drug. In fact, there was a trend towards adverse events being reported more often in the placebo group, suggesting that vitamin D~3~ possibly could be efficient against other diseases, but this observation requires further studies. No clinically relevant changes of blood chemistry (calcium, phosphate, albumin or creatine) were observed. Despite few adverse events and high tolerability, 16 exclusions occurred during the study year. The main reason was problems to adhere to the protocol and 6/16 patients dropped out of the study after a few weeks. The rest failed to send in the diaries, did not leave blood for monitoring of safety parameters or did not take the study drug. One patient was excluded based on symptoms that could be attributed to vitamin D~3~ (facial paraesthesia). However, this patient was later confirmed to have been allocated to placebo.

In summary, we found that supplementation with vitamin D~3~ reduced the total infectious score with 47 points per patient (23% reduction in the adjusted analysis) during the study year. The observed reduction was lower than the assumed reduction of 70 points per patient (predefined assumption: 210 points=\>140 points; a reduction of 30%) that formed the basis for the power calculation. However, despite the predefined level of a reduction of infectious score by 30% as a clinically meaningful effect, we believe that effects lower than this also could be relevant for the individual patient. We base this line of reasoning on the fact that a reduction of 47 points per patient can be translated into 47 days with cough (47 points), 23 days with ear and sinus symptoms (23×2=46 points) or 9 days with cough, sinus and ear symptoms together with malaise and antibiotics (9×5=45 points). In addition, our data indicate that vitamin D~3~ supplementation reduces the odds of taking antibiotics by approximately 60% in patients with frequent respiratory tract infections. Thus, supplementation with vitamin D~3~ could provide a novel strategy to reduce antibiotic use among high consumers and indirectly prevent the emerging epidemic of bacterial resistance.
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